Free tool
FAERS Monitor: Leqselvi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217900 or its brand name (Leqselvi, Deuruxolitinib Phosphate). Reports on generic versions are filed under their own applications.
Reports
174
Serious
0
0% of reports
Hospitalization
0
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
Nothing to show.
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 12 |
| 2026 | 162 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,985 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.